Following the initial description of targeted treatment with L-serine in an individual with GRIN2B-related disorder due to a pathogenic loss-of-function missense variant in the context of an n-of-1 trial [8], ten European individuals with GRIN-related neurodevelopmental disorders that received L-serine were identified. Here, GRIN2B is linked to neurodevelopmental disorder.